These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18088578)

  • 1. [Treatment of secondary hyperparathyroidism in dialysis: Report of a case-study of treatment failure].
    Pruijm MT; Teta D; Wuerzner G; Santschi V; Burnier M
    Nephrol Ther; 2008 Feb; 4(1):28-33. PubMed ID: 18088578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet cost and utility in dialysis patients.
    Cohen E; Uribarri J
    Semin Dial; 2005; 18(4):353-4. PubMed ID: 16076364
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
    Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
    Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress in the treatment of secondary hyperparathyroidism. Role of calcimimetics].
    Sułowicz W
    Przegl Lek; 2006; 63 Suppl 3():3-9. PubMed ID: 16898475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].
    Mpio I; Boumendjel N; Karaaslan H; Arkouche W; Lenz A; Cardozo C; Cardozo J; Pastural-Thaunat M; Fouque D; Silou J; Attaf D; Laville M
    Nephrol Ther; 2011 Jul; 7(4):229-36. PubMed ID: 21353659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients.
    Hirai T; Nakashima A; Takasugi N; Yorioka N
    Ther Apher Dial; 2010 Dec; 14(6):577-82. PubMed ID: 21118366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.
    Yokoyama K
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1405-8. PubMed ID: 19696214
    [No Abstract]   [Full Text] [Related]  

  • 10. [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].
    Reichel H; Braun J
    Dtsch Med Wochenschr; 2011 Jan; 136(4):123-8. PubMed ID: 21181622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
    Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of parathyroid gland swelling by treatment with cinacalcet.
    Terawaki H; Nakano H; Takeguchi F; Hasegawa T; Nakayama M; Okazaki M; Hosoya T
    Nephrol Dial Transplant; 2009 Feb; 24(2):690-1; author reply 691-2. PubMed ID: 18987257
    [No Abstract]   [Full Text] [Related]  

  • 13. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
    Mercadal Orfila G; Blasco Mascaró I
    Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcimimetics versus parathyroidectomy: What is preferable?
    Rroji M; Spasovski G
    Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of vascular calcification in a patient treated with cinacalcet: a case report.
    Salgueira M; Martínez AI; Milán JA
    Nefrologia; 2011; 31(5):602-6. PubMed ID: 21959728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.
    Evenepoel P; Sprangers B; Lerut E; Bammens B; Claes K; Kuypers D; Meijers B; Vanrenterghem Y
    Clin Transplant; 2012; 26(3):393-402. PubMed ID: 22007637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
    Esteve Simo V; Moreno-Guzmán F; Martínez Calvo G; Fulquet Nicolas M; Pou Potau M; Macias-Toro J; Duarte-Gallego V; Saurina Sole A; Ramírez-de Arellano Serna M
    Nefrologia; 2015; 35(4):403-9. PubMed ID: 26306967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in secondary hyperparathyroidism due to drug adherence monitoring in dialysis patients.
    Pruijm M; Teta D; Halabi G; Wuerzner G; Santschi V; Burnier M
    Clin Nephrol; 2009 Sep; 72(3):199-205. PubMed ID: 19761725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fooling the parathyroid gland--will there be health benefits?
    Curhan G
    N Engl J Med; 2004 Apr; 350(15):1565-7. PubMed ID: 15071132
    [No Abstract]   [Full Text] [Related]  

  • 20. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.